Settlements for generic and biosimilar drugs have led to significant healthcare cost savings, although delays in market entry still persist for some products. Despite agreements accelerating potential entry for drugs like Welchol, Integrilin, Aggrastat, and Istodax, regulatory and supply chain challenges have hindered their availability. While patent disputes are resolved through settlements, other factors can […]